Drug
Tagrisso
Tagrisso is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Active, not recruiting1
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)
Trials by Status
active_not_recruiting133%
unknown133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingnot_applicable
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
NCT03969823
recruitingphase_1
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT06306456
unknownphase_2
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
NCT02824952
Clinical Trials (3)
Showing 3 of 3 trials
NCT03969823Not Applicable
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
NCT06306456Phase 1
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT02824952Phase 2
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3